Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best US stocks to buy and hold in 2026. On January 20, Wells Fargo adjusted its outlook on Alnylam Pharmaceuticals, lowering the price target to $376 from $479 while maintaining an Equal Weight rating. While the firm increased its 2026 revenue estimates for Amvuttra by 6%, it expressed concern over rising costs. Specifically, the firm expects R&D expenses to climb to ~30% of total revenue between 2026 and 2030. This reinvestment is projected to compress operating margins to roughly 30%.

On the same day, RBC Capital reduced its price target for Alnylam to $465 from $500 while maintaining an Outperform rating. This adjustment followed a meeting with the company’s management team to discuss the 2026 net product revenue outlook. Management addressed recent performance for Amvuttra, explaining that a soft November resulted from a few one-off factors, which were followed by an impressive December.

Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression

jason-briscoe-Gw_sFen8VhU-unsplash

Earlier on January 12, Needham increased its price target for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from $520 to $529 with a Buy rating following the company’s Q4 2025 pre-announcement and the release of its 2026 financial outlook.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.